[O13] Oral Session 13　Lung Cancer / Thoracic Cancer 3（Rare gene alterations）
【E】

[O13-3] Primary Data from DESTINY-Lung01: A Phase 2 Trial of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

^○Yasushi Goto¹, Bob T. Li², Egbert F. Smit³, Kazuhiko Nakagawa⁴, Hibiki Udagawa⁵, Julien Mazières⁶, Misako Nagasaka⁷, Lyudmila Bazhenova⁸, Andreas N. Saltos⁹, Enriqueta Felip¹⁰, Jose M. Pacheco¹¹, Maurice Pérol¹², Luis Paz-Ares¹³, Kapil Saxena¹⁴, Ryota Shiga¹⁴, Yingkai Cheng¹⁴, Suddhasatta Acharyya¹⁴, Javad Shahidi¹⁴, David Planchard¹⁵, Pasi A. Jänne¹⁶ (1.Department of Thoracic Oncology, National Cancer Center Hospital, 2.Memorial Sloan Kettering Cancer Center, New York, NY, USA, 3.Netherlands Cancer Institute, Amsterdam, Netherlands, 4.Kindai University Hospital, Osaka, Japan, 5.National Cancer Center Hospital East, Chiba, Japan, 6.Institut Universitaire du Cancer, Toulouse, France, 7.Karmanos Cancer Institute, Detroit, MI, USA, 8.University of California San Diego Moores Cancer Center, San Diego, CA, USA, 9.Moffitt Cancer Center, Tampa, FL, USA, 10.Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain, 11.University of Colorado, Aurora, CO, USA, 12.Centre Léon Bérard, Lyon, France, 13.Hospital Universitario 12 de Octubre, Madrid, Spain, 14.Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 15.Gustave Roussy, Villejuif, France, 16.Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, USA)